Craig C Beeson

US Patent:

20040115207, Jun 17, 2004

Filed:

Mar 19, 2003

Appl. No.:

10/181311

Inventors:

Bernstein Irwin - Seattle WA, US
Peter Senter - Seattle WA, US
Craig Beeson - Charleston SC, US
Michael Hart - Seattle WA, US

International Classification:

A61K051/00
A61K039/395
C07K016/46

US Classification:

424/178100, 424/001490, 530/391100

Abstract:

A novel bioconjugate and a method for delivering the bioconjugate to a cell site is described. In particular, the bioconjugate composition comprises a targeting agent conjugated to a diagnostically or therapeutically effective agent by a metabolizable linker moiety which is cleaved by an exogenous enzyme.

US Patent:

20070054875, Mar 8, 2007

Filed:

Sep 8, 2006

Appl. No.:

11/517977

Inventors:

Giuseppe Gumina - Charleston SC, US
Craig Beeson - Charleston SC, US
Gary Wright - Charleston SC, US

International Classification:

A61K 31/7076

US Classification:

514045000

Abstract:

Disclosed herein are compounds having Formula I, which are non-natural L-adenosine analogs. Also disclosed are their methods of making. Still further, disclosed are the uses of the disclosed compounds to treat cardiovascular disease, ischemia related injuries, and neurodegenerative diseases.

US Patent:

20130137728, May 30, 2013

Filed:

Mar 24, 2011

Appl. No.:

13/636754

Inventors:

Craig Cano Beeson - Charleston SC, US
Baerbel Rohrer - Charleston SC, US
Nathan Perron - Charleston SC, US

Assignee:

MUSC Foundation For Research And Development - Charleston SC

International Classification:

C07D 417/14
C07D 401/04
C07D 401/08
C07D 417/04

US Classification:

514339, 435 29, 435375, 514342, 5462704, 5462777

Abstract:

Disclosed are compounds or pharmaceutically acceptable salts thereof, having the structure of formula I. Also disclosed are methods of preventing and/or treating degenerative disease in a subject, comprising administering to said subject a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions for preventing and/or treating de-generative disease in a subject comprising a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

US Patent:

20140024677, Jan 23, 2014

Filed:

Apr 9, 2013

Appl. No.:

13/859546

Inventors:

Craig C. BEESON - Mount Pleasant SC, US
Yuri K. PETERSON - James Island SC, US

Assignee:

MUSC Foundation For Research Development - Charleston SC

International Classification:

A61K 31/4704
A61K 31/138
A61K 31/137

US Classification:

514312, 514653, 514651

Abstract:

Methods and compositions for inducing mitochondrial biogenesis are provided. In some aspects, methods for the treatment of diseases such as acute kidney disease (AKI) or a muscle wasting disease by administering tomoxetine, nisoxetine, fenoterol, formoterol, or procaterol to an individual are provided.

US Patent:

20200055827, Feb 20, 2020

Filed:

Nov 2, 2017

Appl. No.:

16/347163

Inventors:

- Charleston SC, US
Craig C. BEESON - Charleston SC, US
Yuri Karl PETERSON - Charleston SC, US
Rick G. SCHNELLMANN - Tucson AZ, US

International Classification:

C07D 239/47
A61P 13/12

Abstract:

Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, promote mitochondrial biogenesis and are useful for the treatment of, for example, acute kidney injury and chronic kidney disease.

US Patent:

20170285045, Oct 5, 2017

Filed:

Mar 29, 2017

Appl. No.:

15/472414

Inventors:

- Charleston SC, US
Christopher Lindsey - Wadmalaw Island SC, US
Craig C. Beeson - Charleston SC, US

International Classification:

G01N 33/84
G01N 33/58
A61K 49/00
C09B 11/08
G01N 21/64

Abstract:

Provided herein is a fluorescent probe compound of formula (I):as well as methods of using said compound.

US Patent:

20170157081, Jun 8, 2017

Filed:

Jul 21, 2014

Appl. No.:

15/328021

Inventors:

- Raisio, FI
Ilmo Pellervo ARONEN - Hinnerjoki, FI
Craig Cano BEESON - Charleston SC, US
Christopher John BUNTEL - Singapore, SG

Assignee:

BENEMILK OY - Raisio

International Classification:

A61K 31/20
A23K 10/30
A61K 36/48
A23K 50/10
A61K 36/899
A23K 30/18
A23K 20/158

Abstract:

Silage compositions are described herein, as well as methods for their preparation and use. A silage composition may include a fatty acid component comprising at least about 70% saturated fatty acid by weight and a fermented component. The fatty acid component may be present in the silage composition in an amount of at least about 10% by weight of the silage composition.

US Patent:

20170081328, Mar 23, 2017

Filed:

May 15, 2015

Appl. No.:

15/307966

Inventors:

- Charleston SC, US
Craig C. Beeson - Charleston SC, US

International Classification:

C07D 471/14

Abstract:

In some aspects, the present invention relates to aza-ellipticine compounds of the formula: wherein the variables are as defined herein. The application also provides novel methods of preparing aza-ellipticine compounds, methods of using the compounds, and pharmaceutical compositions thereof.